Adrian von Witzleben1,2, Eve Currall1, Oliver Wood1, Lindsey Chudley1, Oluyemisi Akinyegun3, Jaya Thomas1, Kaïdre Bendjama4, Gareth J Thomas1,3, Peter S Friedmann1, Emma V King1,5, Simon Laban2, Christian H Ottensmeier1,6. 1. CRUK and NIHR Experimental Cancer Medicine Center & School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom. 2. Department of Otorhinolaryngology, Head & Neck Surgery, University of Ulm, Ulm, Germany. 3. Southampton University Hospitals NHS Foundation Trust, Southampton, United Kingdom. 4. Department Affaires Médicinales, Research, Project, Transgene SA, Illkirch, France. 5. Department of Otorhinolaryngology, Head & Neck Surgery, Poole Hospital, Poole, United Kingdom. 6. Liverpool Head and Neck Centre, Institute of Translational Medicine, Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.
Abstract
INTRODUCTION: Human papillomavirus 16 (HPV16) is the main cause of oropharyngeal squamous cell carcinoma (OPSCC). To date, the links between HPV16 gene expression and adaptive immune responses have not been investigated. We evaluated the correlation of HPV16 DNA, RNA transcripts and features of adaptive immune response by evaluating antibody isotypes against E2, E7 antigens and density of tumor-infiltrating lymphocytes (TIL). MATERIAL AND METHODS: FFPE-tissue from 27/77 p16-positive OPSCC patients was available. DNA and RNA were extracted and quantified using qPCR for all HPV16 genes. The TIL status was assessed. Immune responses against E2 and E7 were quantified by ELISA (IgG, IgA, and IgM; 77 serum samples pre-treatment, 36 matched post-treatment). RESULTS: Amounts of HPV16 genes were highly correlated at DNA and RNA levels. RNA co-expression of all genes was detected in 37% (7/19). E7 qPCR results were correlated with higher anti-E7 antibody (IgG, IgA) level in the blood. Patients with high anti-E2 IgG antibody (>median) had better overall survival (p=0.0311); anti-E2 and anti-E7 IgA levels had no detectable effect. During the first 6 months after treatment, IgA but not IgG increased significantly, and >6 months both antibody classes declined over time. Patients with immune cell-rich tumors had higher levels of circulating antibodies against HPV antigens. CONCLUSION: We describe an HPV16 qPCR assay to quantify genomic and transcriptomic expression and correlate this with serum antibody levels against HPV16 oncoproteins. Understanding DNA/RNA expression, relationship to the antibody response in patients regarding treatment and outcome offers an attractive tool to improve patient care.
INTRODUCTION: Human papillomavirus 16 (HPV16) is the main cause of oropharyngeal squamous cell carcinoma (OPSCC). To date, the links between HPV16 gene expression and adaptive immune responses have not been investigated. We evaluated the correlation of HPV16 DNA, RNA transcripts and features of adaptive immune response by evaluating antibody isotypes against E2, E7 antigens and density of tumor-infiltrating lymphocytes (TIL). MATERIAL AND METHODS: FFPE-tissue from 27/77 p16-positive OPSCC patients was available. DNA and RNA were extracted and quantified using qPCR for all HPV16 genes. The TIL status was assessed. Immune responses against E2 and E7 were quantified by ELISA (IgG, IgA, and IgM; 77 serum samples pre-treatment, 36 matched post-treatment). RESULTS: Amounts of HPV16 genes were highly correlated at DNA and RNA levels. RNA co-expression of all genes was detected in 37% (7/19). E7 qPCR results were correlated with higher anti-E7 antibody (IgG, IgA) level in the blood. Patients with high anti-E2 IgG antibody (>median) had better overall survival (p=0.0311); anti-E2 and anti-E7 IgA levels had no detectable effect. During the first 6 months after treatment, IgA but not IgG increased significantly, and >6 months both antibody classes declined over time. Patients with immune cell-rich tumors had higher levels of circulating antibodies against HPV antigens. CONCLUSION: We describe an HPV16 qPCR assay to quantify genomic and transcriptomic expression and correlate this with serum antibody levels against HPV16 oncoproteins. Understanding DNA/RNA expression, relationship to the antibody response in patients regarding treatment and outcome offers an attractive tool to improve patient care.
Authors: Anusha-Preethi Ganesan; James Clarke; Oliver Wood; Eva M Garrido-Martin; Serena J Chee; Toby Mellows; Daniela Samaniego-Castruita; Divya Singh; Grégory Seumois; Aiman Alzetani; Edwin Woo; Peter S Friedmann; Emma V King; Gareth J Thomas; Tilman Sanchez-Elsner; Pandurangan Vijayanand; Christian H Ottensmeier Journal: Nat Immunol Date: 2017-06-19 Impact factor: 25.606
Authors: Sri Krishna; Peaches Ulrich; Eric Wilson; Falguni Parikh; Pooja Narang; Shanshan Yang; Amelia K Read; Seunghee Kim-Schulze; Jin G Park; Marshall Posner; Melissa A Wilson Sayres; Andrew Sikora; Karen S Anderson Journal: Cancer Res Date: 2018-08-28 Impact factor: 12.701
Authors: Jian Ye; George Coulouris; Irena Zaretskaya; Ioana Cutcutache; Steve Rozen; Thomas L Madden Journal: BMC Bioinformatics Date: 2012-06-18 Impact factor: 3.169
Authors: K S Anderson; J Wong; G D'Souza; A B Riemer; J Lorch; R Haddad; S I Pai; J Longtine; M McClean; J LaBaer; K T Kelsey; M Posner Journal: Br J Cancer Date: 2011-06-07 Impact factor: 7.640
Authors: Andrew G Schache; Ned G Powell; Kate S Cuschieri; Max Robinson; Sam Leary; Hisham Mehanna; Davy Rapozo; Anna Long; Heather Cubie; Elizabeth Junor; Hannah Monaghan; Kevin J Harrington; Christopher M Nutting; Ulrike Schick; Andy S Lau; Navdeep Upile; Jon Sheard; Kath Brougham; Catharine M L West; Ken Oguejiofor; Steve Thomas; Andy R Ness; Miranda Pring; Gareth J Thomas; Emma V King; Dennis J McCance; Jacqueline A James; Michael Moran; Phil Sloan; Richard J Shaw; Mererid Evans; Terry M Jones Journal: Cancer Res Date: 2016-08-28 Impact factor: 13.312